Treatment of Simultaneous Arterial and Venous Thrombosis

Pathophysiology and Risk Factors

Patients with myeloproliferative disorders are at increased risk for both arterial and venous thrombotic events 1

Low molecular weight heparin (LMWH) is recommended for the initial 5-10 days of anticoagulation in patients with established venous thromboembolism 2
For critical arterial occlusions, endovascular or surgical thrombectomy may be necessary 3
For massive venous thrombosis, catheter-directed thrombolysis or mechanical thrombectomy may be considered 4

For most patients with simultaneous arterial and venous thrombosis, anticoagulation should be continued for at least 6 months 2
In patients with active malignancy or ongoing risk factors, extended anticoagulation beyond 6 months is recommended 2
For patients with recent coronary stenting or acute coronary syndrome, a period of combined therapy may be necessary 5

For patients with cancer who develop both arterial and venous thrombosis, LMWH is preferred for long-term anticoagulation 2
Risk assessment should be performed to identify high-risk patients who may benefit from more aggressive antithrombotic strategies 2

Patients with myeloproliferative disorders who develop arterial and venous thrombosis require cytoreductive therapy in addition to anticoagulation 1
Hydroxyurea is recommended as first-line cytoreductive therapy to target platelet count and WBC count 6
Low-dose aspirin should be added to the regimen once adequate control of platelet counts is achieved 1

For patients with dialysis access thrombosis involving both arterial and venous components, endovascular techniques are preferred as first-line therapy 4
Surgical thrombectomy may be considered for forearm arteriovenous fistulas with juxta-anastomotic stenoses 4

Regular monitoring of anticoagulation therapy is essential, with vitamin K antagonists maintaining INR in the therapeutic range (typically 2.0-3.0) 5
Assess for signs of recurrent thrombosis or bleeding complications at each follow-up visit 2
Evaluate the need for continued dual therapy at 1, 3, and 6 months 5

Bleeding risk is significantly increased with combined anticoagulant and antiplatelet therapy, with addition of single antiplatelet therapy increasing bleeding risk by 20-60% 5
Triple therapy increases bleeding risk 2-3 fold 5
In patients with recurrent thrombosis despite adequate anticoagulation, evaluate for underlying disorders such as antiphospholipid syndrome, cancer, or myeloproliferative disorders 2
For patients with mechanical heart valves who develop venous thrombosis, vitamin K antagonists remain the anticoagulant of choice 5